On May 23, 2007, the FDA took yet another step in its constantly-growing level of regulation over gadolinium, a substance that’s been an ingredient in several popular contrasting agents used to help doctors review MRI’s and MRA’s. This represents the strongest step yet that’s been taken by the federal government.

According to the FDA, the following products were singled out as being potentially problematic for certain patients:

• Magnevist (gadopentetate dimeglumine)
• Ominiscan (gadodiamide)
• OptiMARK (gadoversetamide)
• MultiHance (gadobenate dimeglumine)
• ProHance (gadoteridol)

This step is simply the latest development in the FDA’s oversight of these products, and these steps date back to June of 2006, with progressively stronger steps being taken every time the FDA gets involved with gadolinium-containing products.

If you have been harmed by gadolinium, you need to seek medical attention and then contact the gadolinium lawyers at Williams Kherkher today for a free consultation.